Cargando…

CLRM-02. TRIAL IN PROGRESS: A PROSPECTIVE, MULTICENTER PHASE 2B STUDY TO ESTABLISH IMAGE INTERPRETATION CRITERIA FOR (18)F-FLUCICLOVINE PET IN DETECTING RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (PURSUE)

BACKGROUND: Brain metastases represent the most common intracranial tumor in adults, occurring in 10-40% of cancer patients. Most patients undergo multimodal treatment approaches and post-treatment follow-up with conventional MRI (CE-T1-weighted and FLAIR/T2-weighted) of the brain is performed to mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotecha, Rupesh, Chaglassian, Alain, Tainer, Nancy, Teoh, Eugene J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453804/ http://dx.doi.org/10.1093/noajnl/vdab112.001

Ejemplares similares

TRLS-01. Trial in Progress: A Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for (18)F-Fluciclovine PET in Detecting Recurrent Brain Metastases after Radiation Therapy (PURSUE)
por: Kotecha, Rupesh, et al.
Publicado: (2021)

TRLS-02. Trial in Progress: A Multicenter Phase 3 Study to Establish the Diagnostic Performance of (18)F-Fluciclovine PET in Detecting Recurrent Brain Metastases after Radiation Therapy (REVELATE)
por: Teoh, Eugene, et al.
Publicado: (2021)

NEIM-03 A MULTICENTER PHASE 3 TRIAL IN PROGRESS: DIAGNOSTIC PERFORMANCE OF(18)F-FLUCICLOVINE PET FOR THE DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (REVELATE)
por: Chao, Samuel, et al.
Publicado: (2022)

NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR(18)F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
por: Kotecha, Rupesh, et al.
Publicado: (2023)

CLRM-11 CURRENT STATE OF CLINICAL TRIALS FOR PATIENTS WITH MELANOMA BRAIN METASTASES
por: Elghawy, Omar, et al.
Publicado: (2022)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

CLRM-13 RELEVANCE OF RECURSIVE PARTITIONING ANALYSIS (RPA) CLASSIFICATION IN THE CURRENT CARE OF PATIENTS WITH BRAIN METASTASES (BMETS)
por: Sarai, Guneet, et al.
Publicado: (2022)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

CLRM-02 SINGLE CENTER EXPERIENCE OF DOPAMINE ANTAGONIST ONC-201 FOR RECURRENT H3K27M-MUTANT GLIOBLASTOMA IN ADULTS
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

BIMG-19. (18)F-FLUCICLOVINE PET/CT TO DISTINGUISH RADIATION NECROSIS FROM TUMOR PROGRESSION IN BRAIN METASTASES TREATED WITH STEREOTACTIC RADIOSURGERY: A PROSPECTIVE PILOT STUDY
por: Tom, Martin
Publicado: (2021)

CLRM-08. TRIAL WORKING GROUPS FOR PAEDIATRIC BRAIN TUMOURS
por: Rahman, Ruman, et al.
Publicado: (2021)

CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS
por: Peters, Katherine
Publicado: (2022)

CLRM-13. INTRAOPERATIVE MICRODIALYSIS: GLIOMA INTELLIGENCE FROM BEHIND ENEMY LINES
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2021)

CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY
por: Ekhator, Chukwuyem, et al.
Publicado: (2022)

CLRM-20 IDENTIFYING RISK FACTORS AND ANALYZING SURVIVAL FOLLOWING PACHYMENINGEAL FAILURE
por: Kalyvas, Aristotelis, et al.
Publicado: (2022)

CLRM-05. DRUG-RELEASING MICRODEVICES TO PREDICT RESPONSES TO TARGETED THERAPIES IN PATIENTS WITH GLIOMAS
por: Blitz, Sarah, et al.
Publicado: (2021)

CLRM-12. HYBRID DESIGNS FOR USING EXTERNAL CONTROLS IN PHASE 3 GLIOBLASTOMA TRIALS
por: Polley, Mei-Yin, et al.
Publicado: (2021)

CLRM-19 USING FUNCTIONAL PRECISION MEDICINE TO GUIDE CLINICAL TRIAL ENROLLMENT IN GBM
por: Ledford, Aubrey, et al.
Publicado: (2022)

CLRM-01. MACHINE LEARNING TO UNCOVER SIGNATURES OF VULNERABILITY IN GLIOBLASTOMA UMBRELLA SIGNATURE TRIAL (GUST)
por: Peng, Sen, et al.
Publicado: (2021)

CLRM-09. INCORPORATING EXTERNAL CONTROL ARM IN MDNA55 RECURRENT GLIOBLASTOMA REGISTRATION TRIAL
por: Davi, Ruthanna, et al.
Publicado: (2021)

CLRM-05 FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMACOKINETICS OF DIFFUSE MIDLINE GLIOMA USING INTRATUMORAL MICRODIALYSIS
por: Dalmage, Mahalia, et al.
Publicado: (2022)

CLRM-14 INTRATUMORAL EXTRACELLULAR METABOLIC IMPACT OF DFMO AND AMXT 1501 IN LIVE HUMAN GLIOMAS
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2022)

In Molecular Pursuit of Bone Metastasis by Fluciclovine PET
por: Lindenberg, Liza
Publicado: (2017)

CLRM-11. BENCH TO BEDSIDE NEURO-ONCOLOGY: ADVOCATING FOR A CLINICALLY RELEVANT STRATEGY AS UNDERSCORED BY THE PANDEMIC
por: Brown, Timothy, et al.
Publicado: (2021)

CLRM-03 INCIDENCE OF INTRACRANIAL HEMORRHAGE IN GLIOMA PATIENTS WITH VENOUS THROMBOEMBOLISM CONVERTED FROM LMWH TO APIXABAN
por: Aboud, Orwa, et al.
Publicado: (2022)

CLRM-17 USE OF EXTERNAL CONTROL DATA FOR PLANNING AND ANALYZING GBM TRIALS: READY FOR PRIME TIME?
por: Polley, Mei-Yin, et al.
Publicado: (2022)

Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy
por: Payne, Heather, et al.
Publicado: (2021)

CLRM-10 METIS (EF-25): A PIVOTAL, RANDOMIZED CONTROLLED STUDY OF TUMOR TREATING FIELDS IN PATIENTS WITH 1–10 BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER
por: Mehta, Minesh, et al.
Publicado: (2022)

CLRM-09 MAPPING THE DISTRIBUTION AND CLINICAL ASSOCIATIONS OF BRAIN METASTASES IN RENAL CELL CARCINOMA
por: Kamson, David Olayinka, et al.
Publicado: (2023)

CLRM-21 RISK FACTORS ASSOCIATED WITH THE PRESENCE OF BRAIN METASTASIS AT THE MOMENT OF DIAGNOSIS IN LUNG CANCER PATIENTS: RETROSPECTIVE CASE SERIES
por: Martín-Abreu, Carla M, et al.
Publicado: (2022)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

CLRM-06 PROSPECTIVE CLINICAL STUDY OF CONVENTIONALLY FRACTIONATED CONCURRENT CHEMORADIOTHERAPY AND HYPOFRACTIONATED CONCURRENT CHEMORADIOTHERAPY AFTER THE SURGERY OF HIGH-GRADE GLIOMAS
por: Weiyan, Shi
Publicado: (2022)

CLRM-04. PHASE I/II SAFETY AND EFFICACY STUDY OF BET BROMODOMAIN INHIBITOR OTX-015 WITH OLAPARIB AND LOMUSTINE IN PATIENTS WITH RECURRENT GLIOBLASTOMA
por: Lam, Fred
Publicado: (2021)

CLRM-07 A MULTIVARIATE RETROSPECTIVE ANALYSIS OF 159 PATIENTS WITH HIGH-GRADE GLIOMAS: OVERALL SURVIVAL, PROGRESSION-FREE SURVIVAL, AND PROGNOSTIC FACTORS
por: Liu, Shiyu, et al.
Publicado: (2022)

CLRM-09 FIRST-LINE Tumor TREATING FIELDS (200 KHZ) THERAPY FOR NEWLY-DIAGNOSED GLIOBLASTOMA: THE PHASE 3 TRIDENT TRIAL (EF-32)
por: Shi, Wenyin, et al.
Publicado: (2022)

Detection of Recurrent Prostate Cancer With (18)F-Fluciclovine PET/MRI
por: Selnæs, Kirsten Margrete, et al.
Publicado: (2020)

CLRM-12 TITLE: STEREOTACTIC RADIOSURGERY (ADJUVANT OR NEOADJUVANT) COMPARED TO HIPPOCAMPAL AVOIDANCE WHOLE BRAIN RADIATION THERAPY WITH SIMULTANEOUS INTEGRATED BOOST FOR LIMITED BRAIN METASTASES (SRS-CHART): PHASE III OPEN-LABEL PARALLEL-GROUP RANDOMIZED CONTROLLED TRIAL
por: Dasgupta, Archya, et al.
Publicado: (2022)

CLRM-07. INCREASING EFFICIENCY IN EARLY PHASE MULTICENTER IMAGING BIOMARKER TRIALS: EMERGING STRATEGIES FROM THE GABLE (GLIOBLASTOMA ACCELERATED BIOMARKER LEARNING ENVIRONMENT) TRIAL
por: Barboriak, Daniel, et al.
Publicado: (2021)

Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
por: Teoh, Eugene J, et al.
Publicado: (2018)

CLRM-02 CALCIFIED SPINAL MENINGIOMAS: A SYSTEMATIC REVIEW OF CLINICAL CHARACTERISTICS, TREATMENT STRATEGIES, AND OUTCOMES
por: Reddy, Raghuram, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n9ng08fk9dqk2kfedhedhucdfm